Cargando…

Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is an aggressive neoplasm with poor clinical outcome because most patients present at an advanced stage, at which point curative surgical options, such as tumor excision or liver transplantation, are not feasible. Therefore, the majority of HCC patients require systemi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaseb, Ahmed O., Haque, Abedul, Vishwamitra, Deeksha, Hassan, Manal M., Xiao, Lianchun, George, Bhawana, Sahu, Vishal, Mohamed, Yehia I., Carmagnani Pestana, Roberto, Lombardo, Jamie Lynne, Avritscher, Rony, Yao, James C., Wolff, Robert A., Rashid, Asif, Morris, Jeffrey S., Amin, Hesham M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582251/ https://www.ncbi.nlm.nih.gov/pubmed/36276070 http://dx.doi.org/10.3389/fonc.2022.986305

Ejemplares similares

Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development
por: Haque, Abedul, et al.
Publicado: (2022)

Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib
por: Mohamed, Yehia I., et al.
Publicado: (2021)

Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
por: Yavuz, Betul Gok, et al.
Publicado: (2020)

Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC
por: Qayyum, Aliya, et al.
Publicado: (2019)

Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2018)

Type I insulin-like growth factor receptor signaling in hematological malignancies
por: Vishwamitra, Deeksha, et al.
Publicado: (2016)

Pegvisomant in acromegaly: an update
por: Giustina, A., et al.
Publicado: (2017)

Prognostic Significance of Serum Insulin-Like Growth Factor-1 in Hepatocellular Cancer Patients: A Validation Study
por: Lacin, Sahin, et al.
Publicado: (2020)

Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2019)

Correction: Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK(+) T-cell lymphoma
por: George, Bhawana, et al.
Publicado: (2023)

Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients
por: Neggers, Sebastian J. C. M. M., et al.
Publicado: (2011)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Pegvisomant for acromegaly: does it always works?
por: Neggers, Sebastian J., et al.
Publicado: (2019)

Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

Brazilian multicenter study on pegvisomant treatment in acromegaly
por: Boguszewski, Cesar L., et al.
Publicado: (2019)

Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study
por: Kuhn, Emmanuelle, et al.
Publicado: (2020)

The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK(+) T-cell lymphoma
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline
por: Giustina, A., et al.
Publicado: (2014)

Safety and Efficacy of Pegvisomant in Pediatric Growth Hormone Excess
por: Tatsi, Christina, et al.
Publicado: (2021)

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2021)

Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy
por: Brue, Thierry, et al.
Publicado: (2018)

Body Composition Changes with Long-term Pegvisomant Therapy of Acromegaly
por: Kuker, Adriana P, et al.
Publicado: (2021)

Pegvisomant in acromegaly: a multicenter real-life study in Argentina
por: Basavilbaso, Natalia Ximena Garcia, et al.
Publicado: (2019)

Validation of an IGF-CTP scoring system for assessing hepatic reserve in egyptian patients with hepatocellular carcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2015)

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients
por: Mohamed, Yehia I., et al.
Publicado: (2022)

Lipodystrophy during pegvisomant therapy: a case report and review of the literature
por: Buyuktas, D, et al.
Publicado: (2010)

In vitro impact of pegvisomant on growth hormone-secreting pituitary adenoma cells
por: Cuny, Thomas, et al.
Publicado: (2016)

The ALK inhibitor ASP3026 eradicates NPM-ALK(+) T-cell anaplastic large-cell lymphoma in vitro and in a systemic xenograft lymphoma model
por: George, Suraj Konnath, et al.
Publicado: (2014)

SUMOylation Confers Posttranslational Stability on NPM-ALK Oncogenic Protein()
por: Vishwamitra, Deeksha, et al.
Publicado: (2015)

Minimally invasive image-guided therapies for hepatocellular carcinoma
por: Abdelsalam, Mohamed E, et al.
Publicado: (2016)

More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY
por: Fleseriu, Maria, et al.
Publicado: (2021)

Analysis of histology-agnostic targets among soft tissue and bone sarcomas in the AACR GENIE database
por: Pestana, Roberto Carmagnani, et al.
Publicado: (2023)

Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
por: Strasburger, Christian J, et al.
Publicado: (2018)

Surgery, Octreotide, Temozolomide, Bevacizumab, Radiotherapy, and Pegvisomant Treatment of an AIP Mutation‒Positive Child
por: Dutta, Pinaki, et al.
Publicado: (2019)

Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDY
por: Grottoli, S., et al.
Publicado: (2022)

Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism
por: Burren, Christine P, et al.
Publicado: (2023)

Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma
por: Kaseb, Ahmed Omar, et al.
Publicado: (2016)

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation
por: Moore, David J, et al.
Publicado: (2009)

Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation
por: Mallea-Gil, Maria Susana, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jr37ccl21ch1vasi57ccp2rel5